To evaluate the predictive value of CHADS2 and CHA2DS2-VASc scores for coronary artery lesions and in-hospital prognosis of patients with acute ST-segment elevation myocardial infarction (STEMI). A total of 524 patients who were diagnosed with STEMI from January 2016 to August 2017 were retrospectively reviewed. The correlation between CHADS2 and CHA2DS2-VASc scores with the patients’ clinical data, number of coronary lesions, Gensini scores, the target vessel and hospitalization time and in-hospital adverse events (AEs) was analyzed. The number of coronary lesions in STEMI patients was mainly single and double lesions. The CHADS2 and CHA2DS2-VASc scores were not meaningful for predicting the number of coronary lesions. However, for left main coronary artery lesion, CHADS2 score was significantly increased when the number increased (P < 0.05), but CHA2DS2-VASc score showed no statistical difference (P > 0.05). The incidence of target lesions in STMEI patients was mainly left anterior descending coronary artery (LAD) and right coronary artery (RCA). The two scores were not meaningful for predicting target lesions (P > 0.05). For the severity of coronary lesions, there was positive correlation between CHADS2 score with Gensini score (P < 0.05), but no exact correlation between CHA2DS2-VASc score and Gensini score (P > 0.05). The stratifications of CHADS2 score and CHA2DS2-VASc score were significantly associated with hospitalization time and adverse events during hospitalization (P < 0.05). The high score group had longer hospitalization time and more AEs during hospitalization than the low score group and the middle group statistically (P < 0.05). CHADS2 score had a certain value to predict the severity of coronary lesion and the presence of left main coronary artery in STEMI. The CHA2DS2-VASc score had no predictive ability to do it. There was no significant value in predicting the number of coronary lesions and the location of the target lesions in STEMI patients. However, both scores had the predictive ability for patient hospitalization and AEs during hospitalization.

中文翻译：

---

CHADS2和CHA2DS2-VASc评分对急性ST段抬高型心肌梗死患者冠状动脉病变及院内预后的预测价值

评价CHADS2和CHA2DS2-VASc评分对急性ST段抬高型心肌梗死（STEMI）患者冠状动脉病变及院内预后的预测价值。回顾性分析了 2016 年 1 月至 2017 年 8 月诊断为 STEMI 的 524 例患者。分析CHADS2和CHA2DS2-VASc评分与患者临床资料、冠脉病变个数、Gensini评分、靶血管及住院时间、院内不良事件（AEs）的相关性。STEMI患者冠状动脉病变数量以单双病变为主。CHADS2 和 CHA2DS2-VASc 评分对预测冠状动脉病变的数量没有意义。而对于左冠状动脉主干病变，CHADS2评分随着数量的增加而显着增加（P < 0.05），但CHA2DS2-VASc评分无统计学差异（P>0.05）。STMEI患者靶病变的发生率主要为左冠状动脉前降支（LAD）和右冠状动脉（RCA）。这两个评分对预测靶病变无意义（P>0.05）。对于冠状动脉病变的严重程度，CHADS2评分与Gensini评分呈正相关（P < 0.05），但CHA2DS2-VASc评分与Gensini评分无确切相关性（P > 0.05）。CHADS2评分和CHA2DS2-VASc评分的分层与住院时间和住院期间的不良事件显着相关（P < 0.05）。高分组住院时间长，住院期间不良事件发生率高于低分组和中分组（P < 0.05）。CHADS2评分对STEMI患者冠状动脉病变严重程度及左冠状动脉主干存在有一定的预测价值。CHA2DS2-VASc 评分没有预测能力。预测STEMI患者冠状动脉病变的数量和靶病变的位置没有显着价值。然而，这两个评分都具有预测患者住院和住院期间 AE 的能力。